Tesla
TSLA
Apple
AAPL
Meta Platforms
META
4
Microsoft
MSFT
5
Petroleo Brasileiro SA Petrobras
PBR
US Stock MarketDetailed Quotes
VTYX Ventyx Biosciences
- 1.320
- -0.010-0.75%
Close Mar 21 16:00 ET
93.89MMarket Cap-0.67P/E (TTM)
1.345High1.280Low968.05KVolume1.310Open1.330Pre Close1.27MTurnover1.95%Turnover RatioLossP/E (Static)71.13MShares5.88052wk High0.37P/B65.46MFloat Cap1.28052wk Low--Dividend TTM49.59MShs Float47.251Historical High--Div YieldTTM4.89%Amplitude1.280Historical Low1.314Avg Price1Lot Size
About Ventyx Biosciences Company
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.
Company Profile
SymbolVTYX
Company NameVentyx Biosciences
Listing DateOct 21, 2021
Issue Price16.00
Founded2018
CEODr. Raju S. Mohan, PhD
MarketNASDAQ
Employees82
Fiscal Year Ends12-31
Address12790 El Camino Real,Suite 200
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92130
Phone1-760-593-4832
Websitehttp://www.ventyxbio.com
Company Executives
- Name
- Position
- Salary
- Dr. Raju S. Mohan, PhD
- Director, Chief Executive Officer and President
- 9.41M
- Dr. John M. Nuss, PhD
- Chief Scientific Officer
- 3.89M
- Matthew Richard Moore
- Chief Operating Officer
- --
- Roy M. Gonzales
- Senior Vice President, Finance, Interim Principal Financial Officer and Interim Principal Accounting Officer
- --
- Dr. Sheila Gujrathi, M.D.
- Executive Chairman of the Board
- 486.29K
- Dr. Allison J. Hulme, PhD
- Director
- 834.42K
- William R. White, J.D.
- Independent Director
- 416.29K
- Somasundaram Subramaniam, M.B.A.
- Independent Director
- 417.35K
- Onaiza Cadoret-Manier
- Independent Director
- 837.34K
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025